Novavax earnings – what to watch ahead of Q3 earnings release
Novaxvax will report its third quarter earning on November 4th after market close.
Novavax earnings – What to expect?
The report will be covering company’s earnings for the third quarter ending September 2021. The consensus EPS forecast for the quarter will be around -$3.91 slightly down from the same quarter last year which was -$3.21, but better than last quarter’s -4.75%.
Novavax outlook and forecasts
Despite the negative numbers on the book, Novavax Incs first approval from the Indonesian authority and the upcoming decisions from other countries like India and Philippines will be the major catalysts that would see the company start to generate revenues from its product sales in the near future. Apart from developing countries who are in urgent need for vaccines, Novavax also finalised a deal with the European Commission for an order of 200 million doses in August. Agreements with other countries for a total of 200 million doses has also inked so far. If everything goes well, Novavax will be a major provider to Gavi, The Vaccine Alliance - with an advance purchase agreement for more than one billion doses.
Based on three Wall Street analysts’ forecast who voted for “strong buy” unanimously, Novavax’s average price target for the next 12 months will be $290.33 with a high forecast of $305.00 and a low forecast of $272.00. The average price target represents a range of 48% to 56% upper margin from the last price of $195.30 on November 2.
Novavax stock – Technical analysis
Looking back, the vaccine maker didn’t get much enjoyment on the reporting day for the past 12 months, in each of the four trailing quarters, share price took a tumble at a significant level from 10% to 21%, largely due to the worse than estimated result. However, the outlook might be a bit different this time.
NVAX earnings price changes
Price one day before
Price one day after
|August 5th 2021||$223.81||$189.89||-15.16%||-3.76||-4.75||20.84%|
|May 10th 2021||$176||$138.18||-21.49%||-2.65||-3.05||13.11%|
|March 1st 2021||$231.23||$205.99||-10.92%||-1.53||-2.7||43.33%|
|November 9th 2021||$89.86||$78.74||-12.37%||2.36||-3.21||206.30%|
Although an earning beat is not expected for Q3, the share price of Novavax has walked out from its low on October 19th and surged by 67% since then. The shining light from the vaccine approval has fuelled up the bullish sentiment for its investors.
From the technical standpoint, the recent rally from the past two weeks has already placed the share price well above the 20-day SMA, nearing its longer term 50 and 100-day SMA, suggesting a solid shift is on the way. Near term, further upward movement faces resistance at the level between $204-$222, the shoulder line commenced the recent drop. Once broken, the recent high at $272 should be in view. Despite the uptrend, if the Q3 earnings report proves to be another disappointment, coincided with the over-bought RSI indicator and the Novaxvax drop in the short term, a notable support near $162 would be the key level to eye on.
Novavax has experienced a rollercoaster year: its share price has shrunk more than half from its high at $331 in February to $112 in October. But this journey appears to be in the past soon with little doubt that the first approval for this belated vaccine maker will start a new chapter and bring more material value to the book. So even though the Q3 earnings report might offer little surprise, it will surely help investors to better evaluate the company from a long-term perspective.
Take your position on over 13,000 local and international shares via CFDs or share trading – and trade it all seamlessly from the one account. Learn more about share CFDs or shares trading with us, or open an account to get started today.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Introducing our best ever web platform
Enhance your spread betting and CFD trading with the new IG Trading platform:
Quicker deals, with one-click execution from lists
Real-time updates, with news and Twitter feeds
Orders to part close, price change alerts, a dark theme and more
Live prices on most popular markets